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We have identified distinct histamine pharmacodynamic response phenotypes in
children with allergic disease utilizing histamine iontophoresis with laser Doppler (HILD).
These response phenotypes may be relevant in guiding therapeutic decision making
for agents targeting the allergic response pathways. However, the reliability of these
response phenotypes has not been assessed. Therefore, we performed HILD in children
with allergic rhinitis and/or asthma on two to three separate occasions. HILD responsetime data were analyzed in NONMEM using a linked effect PKPD model. Examination of
observed vs. classified response phenotypes predicted response plots and the sum of
residuals. The intraclass correlation coefficient (ICC) was used to determine the reliability
of phenotype classification. Eighty-two percent of children exhibited a reliable histamine
response phenotype [intraclass correlation coefficient 0.77 (95% CI 0.44–0.93]. These
preliminary results suggest moderate reliability of HILD response phenotype in children.
Further exploration is needed to determine contributions to phenotype variability.
Keywords: histamine, children, pharmacodynamics, allergy, phenotype

INTRODUCTION
Histamine is a small molecule that is released by various cells throughout the body. The amine is
most commonly associated with the allergic response whereby when binding to the Histamine-1
receptor (H1R) it sets off a cascade of responses that lead to itching, sneezing, mucous production,
and bronchoconstriction. However, recently histamine has been discovered to have pervasive effects
throughout the body which include the respiratory system, gastrointestinal tract, central nervous
system, bone marrow, cardiovascular system, genitourinary system, as well as immunoregulatory
effects (Huang and Thurmond, 2008; Thurmond et al., 2008). Due to the broadened understanding
of histamine, it has been suggested that the amine plays a more significant role in the pathogenesis
of diseases such as asthma and atopic dermatitis than previously believed.
Asthma is a heterogeneous disease of various phenotypes (e.g., allergic asthma vs.
non-allergic asthma) in addition to variability in pathophysiology among more defined
disease phenotypes (e.g., multi-allergen sensitivity vs. limited allergen sensitivity). Evidence
suggests that some patients with specific asthma phenotypes may benefit from antiallergic treatment in the management of the disease more than others (Warner and
ETAC Study Group, 2001). However, biomarkers are needed to determine which patients
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may benefit most from the addition of anti-allergic/antihistamine
treatment. The epicutaneous histamine “skin prick” test is
the “gold standard” method for the clinical evaluation of
allergic conditions and is utilized in clinical trials to assess
antihistamine pharmacodynamic response (Deschamps et al.,
2000; Simons and Simons, 2005). The epicutaneous histamine
“skin prick” test involves manually delivering histamine to
the epicutaneous surface of the skin via “prick” device and
the response to histamine is assessed by utilizing a visual
measuring device (e.g., caliper device) to determine the size
of the wheal and flare response after a given period of time.
This method is limited in providing an objective assessment
of histamine pharmacodynamic response. These limitations
include (1) intra-operator and device variability in histamine
delivery, (2) inability to administer a fixed dose of histamine, (3)
operator subjectivity in assessing the wheal and flare response,
(4) inability to continuously assess response, and (5) somewhat
invasive/irritating nature of the procedure which limits its use in
very young children.
Histamine iontophoresis with laser Doppler (HILD) is
an alternative method to assess histamine pharmacodynamic
response in children and adults that overcomes the stated
limitations of the epicutaneous “skin prick” test. HILD allows
a fixed dose of histamine to be delivered into the skin noninvasively, and blood flow response is measured via a laser
Doppler flowmetry device in an objective, continuous, and
dynamic manner. Therefore, this method may be more suitable
for characterizing histamine pharmacodynamics response that
the epicutaneous skin test procedure.
Previously, we have shown that HILD provides an objective,
continuous, and dynamic measurement of histamine response in
both adults and children (Jones et al., 2009, 2013). Furthermore,
we have demonstrated that there are distinct histamine
response phenotypes: Hypo-responsive, Normo-responsive, and
Hyper-responsive (Jones et al., 2013). We also observed that
histamine pharmacodynamic response is associated with genetic
polymorphisms that may augment response at the histamine
receptor sites or alter enzymatic degradation of histamine (Jones
et al., 2016). Therefore, HILD may be useful in determining
differences in the biological response to histamine that may be
driven by genetic makeup.
We believe that observed histamine pharmacodynamics
response phenotypes may be useful in predicting which children
may have a more exaggerated response to histamine and
therefore may benefit most from treatment with anti-allergic
therapies. However, further validation of this tool is necessary.
Therefore, we aimed to determine the intra-individual reliability
of observed histamine response phenotypes in children as the
next step in validating HILD as a suitable biomarker of histamine
pharmacodynamics response.

Children with allergic rhinitis aged 7–19 years of age were
recruited via convenience sampling from the Children’s Mercy
Allergy/Asthma/Immunology clinics after obtaining parental
permission and where appropriate (i.e., age ≥7 years), child
assent or consent.

MATERIALS AND METHODS

Model Development

HILD
Histamine iontophoresis with laser Doppler was performed
in nineteen participants in identical fashion on 2–3 separate
occasions. HILD was conducted following a wash-out period
from the use of agents that alter histamine response (e.g.,
antihistamines – 10 days, systemic steroids – 30 days, and
tricyclic antidepressants – 30 days). For iontophoresis and
Doppler monitoring, a solid-state, single-frequency laser probe
was inserted into the center of an iontophoresis chamber attached
to a laser Doppler blood flow monitor (DRT4, Moor Instruments
Ltd., Wilmington, DE, United States) and placed on the volar
surface of the forearm. A second laser Doppler control probe
placed at a distance of at least 1 cm from the iontophoresis
site. 200 µL of histamine dihydrochloride solution (1%; Sigma
Chemical Ltd., Dorset, United Kingdom), dissolved in a 2%
methylcellulose gel (Sigma-Aldrich Chemical Co., St. Louis, MI,
United States), was placed in the reservoir of the iontophoresis
chamber. For iontophoresis, constant anodal current (50 µA)
was applied and values for small vessel blood flow at each of
the probe sites were calculated by accompanying software (Moor
Instruments Ltd., Devon, United Kingdom) and were expressed
in perfusion units (flux, photocurrent produced by the scattering
of light by moving red blood cells). Baseline blood flow was
assessed for 2 min before the iontophoresis procedure. Blood
flow was monitored continuously until measurements returned
to baseline or for a maximum of 2 h. A more detailed description
of the HILD test has been previously published (Jones et al., 2009,
2013). An example of the HILD setup is provided in Figure 1.

Data Handling
A total of 26 HILD tests were available to assess reliability.
Each response-time profile was examined individually. Of the 19
participants, 11 participants had evaluable data for more than
one HILD test. Four participants had usable profiles for three
tests, and the remaining patients had usable profiles for two tests.
Flux measurements were sampled at 50 Hz for up to 2 h in
each participant who produced a maximum of 3600 data points
per profile. To allow for easier handling for pharmacometric
software, the data were paired down as previously described in
detail (Liu et al., 2016). Briefly, the data were divided evenly
into 200-time segments. The response data were then averaged
within each segment, and the median time of each segment was
used. Finally, 10–15 data points per profile were selected that
provided a realistic representation of the response-time profile.
These reduced data were then used for pharmacometric analysis.

The response-time data were analyzed using NONMEM v7.3
(ICON Development Solutions, Ellicott City, MD, United States).
Pearl-speaks-NONMEM (PsN) 4.4.8 and Pirana 2.9.6 were used
to facilitate model development. A previously published direct

Participants
The protocol for this study was approved by the Children’s
Mercy Institutional Review Board (IRB # 11120477).
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FIGURE 1 | Illustration of the HILD set up. Left most panel – shows the instrumentation set up. Middle left panel – shows the delivery of the drug through the positive
terminal. Middle right panel – shows the transmission of the laser into the tissue and the return of the scattered light which is detected by the photo detector. Right
panel – shows an example histamine (flux) profile over time. Images in the first two panels provided with permission and courtesy of Moor Instruments.

linked PK/PD model based on 156 children (single tests) (Liu
et al., 2016) was used initially to guide model development.
The model was a one-compartment PK model with first-order
absorption and a direct-response fractional Emax PD model. The
initial run using this model failed to converge due to the small
sample size, which did not support the covariate structure. It was
decided to add the current data to the previous dataset to provide
robust individual estimates.

RESULTS
Demographics
Nineteen children with asthma and/or allergic rhinitis were
enrolled for this study. Participants age ranged from 8 to 19 years;
64% were male. Most participants were Caucasian (36%) or
African American (45%) (Table 1).

Phenotype Response Classification

Classification of Histamine Phenotypes

Figure 2 demonstrates the distribution of mean residuals for the
three phenotype groups. The median (range) for the mean of
residuals were −30.5 (−85.3 to −7.98), 0.26 (−17.9 to 19.24),
and 42.23 (−2.4 to 161.9) for the hypo-, normo-, and hyperresponse phenotypes, respectively. A tolerance level of −15 was
chosen for the hypo-responsive group, and a tolerance level of
+8 was chosen for the hyper-responsive group. Values between
these tolerance levels were considered as normo-responsive.
Of the 41 profiles that were not originally assigned to a
phenotype group, two were assigned to the hypo- phenotype,
24 to the normo- phenotype, and 15 to the hyper- phenotype
using this method.

Each response-time profile was assigned to one of three
phenotype groups; hypo-, normo, or hyper-response based
on pharmacodynamic parameters and visual inspection of
individual predicted response vs. observed response plots as
described previously (Jones et al., 2013). To objectively assign
response phenotypes to these profiles, a method was developed
using residuals (observed values – predicted values) derived
from the pharmacometric analysis. For the profiles that could
be assigned phenotype classification based visual inspection, the
mean of the residuals for each profile was determined. The mean
residuals for each profile were then plotted by phenotype group
and examined. A tolerance level was then selected for the hypoand hyper-responsive groups to reduce the amount of overlap
with the normo-responsive group. The remaining response-time
profiles were then assigned to a phenotype group based on the
mean of residuals.

TABLE 1 | Demographic characteristics of all participants with two or more HILD
tests (n = 11).
Characteristic (n = 11)

Reliability of Histamine Phenotype
Classification

Age (y)
BMI (kg/m2 )

The reliability of the histamine phenotype classification was
determined for participants with two or more useable HILD
profiles. The intraclass correlation coefficient (ICC) (Koo and
Li, 2016) was calculated using the “ICC” package (v2.3.0) in R
(v3.3.2). The ICC statistic can be used for test-retest purposes
(Koo and Li, 2016).
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Median (Range), % or N
11 (8–19)
20.1 (15.8–26.4)

Sex (male)

64

Asthma diagnosis

27

Race

3

Caucasian

4

African American

5

Asian
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cohort was 0.77 (95% CI 0.44–0.93) suggesting a moderately
reliable phenotype.

DISCUSSION
Histamine pharmacodynamic response phenotype as determined
by HILD in children with allergic disease and/or asthma appears
reliable based on our study findings. These data are essential
as a next step in validating this potential biomarker in aiding
therapeutic decision making in the use of anti-allergic/antihistaminergic agents.
We have previously revealed that children with a hyperresponsive histamine response phenotype demonstrated higher
AUEC, Emax, and Tmax values when compared to children
classified as hypo-responsive phenotype based on observed vs.
predicted plot visualizations (Jones et al., 2013). However, in this
study, we also identified additional objective criteria to determine
histamine response phenotype classification based on residual
values, which is vital in the future evaluation of this biomarker
to predict therapeutic response. Forty-one children were not able
to be classified by observed vs. predicted plot visualization. As
the majority of the observed vs. predicted plots were able to be
clearly classified by visual inspection, there remains a segment of
the profiles which are not easily discernable visually and therefore
may lead to more subjective classification. A majority (58%) of
these profiles were classified as normo-responsive by residual
value classification. The residual value classification appears to
provide an additional layer of objective classification, especially
for non-readily apparent phenotypes and allow validation of
visually observed plot phenotype classifications. This approach
allows for improved phenotype classification reliability overall.
The moderate reliability of response phenotype classification
in our study was likely partially due to our limited sample
size. Although the majority of participants demonstrated reliable
histamine response classification with repeat assessment, there
were two participants whose classification changed from hyperresponsive to hypo-responsive and vice versa. Larger sample
size would produce a more robust estimate of the confidence
in the reliability of the phenotype classification via HILD.

FIGURE 2 | Scatterplots of the individual mean of residuals grouped by
response phenotype. Dots represent the mean of residuals from each profile
included in analysis. Red lines represent the median and interquartile range of
the data. The dotted lines (–15 and +8) show the tolerance level of defining
the response phenotype (mean of residuals > +8 is classified as
hyper-responsive, mean of residuals < –15 is classified as hypo-responsive,
and ≥ –15 or ≤ +8 is classified as normo-responsive).

Reliability of Phenotype Classification
All four participants with four useable profiles had the same
phenotype classification for each test. Five of the seven
participants with two useable profiles had the same phenotype
classification. One participant’s histamine response classification
was initially hyper-response for the first test and subsequently
was classified as hypo-response for the second test (Figure 3).
The other participant had their histamine response classified as
hypo-response on the first test and then hyper-response on the
second test (Figure 3). The ICC of the HILD in this patient

FIGURE 3 | Scatterplot of observed vs. population predicted flux (response) for participants 54 and 68 demonstrate variability between measurements. Open
squares represent individual flux values collected during each HILD measurement. Blue line is the line of unity. Participant 54 – on Visit 1 the mean of residuals was
+26.5 (classified as hyper-responsive) and on Visit 2 the mean of residuals was –24.4 (classified as hypo-responsive). Participant 68 – on Visit 1 the mean of
residuals was –7 (classified as normo-responsive) and on Visit 2 the mean of residuals was +20.8 (classified as hyper-responsive).
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clinical response to anti-allergic treatment. Future studies are
also necessary in a larger sample size that considers the impact
of changes in disease pathophysiology and/or disease state on
pharmacodynamic response phenotype to further validate this
technique and its utility in aiding therapeutic decision making
for allergic/inflammatory diseases.

We did not identify the difference in phenotype reliability based
on reported demographic characteristics. However, it is plausible
that changes in underlying disease pathophysiology such as atopy
and/or disease state (e.g., controlled vs. uncontrolled disease or
allergic flare vs. stable allergic symptomatology) may be relevant
to changing phenotype classification. These factors were not able
to be considered in this study. Further investigation is required to
determine the basis of response phenotype changes.
While HILD provides an objective, continuous, and
dynamic measurement of histamine response compared to
the epicutaneous histamine “skin prick” test, the method does
have some limitations. Due to the sensitivity of microvascular
measurements, the flowmetry is sensitive to movement.
A majority of response-time profiles that were discarded were
due artifact related to excessive movement during the procedure.
Doppler flowmetry measurements were obtained post histamine
administration in participants until flux values returned to prehistamine baseline flux values or for a maximum duration of
2 h. During this time, the participant is made as comfortable as
possible and is entertained with activities that require minimal
movement (e.g., movie). However, the requirement for limited
movement is a challenge, especially in the pediatric population.
It may be possible to optimize further the method such that early
data such as Emax and Tmax are sufficient to provide a phenotype
classification which would be more ideal as a therapeutically
useful biomarker.
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